# France Microbiome Sequencing Services Market

> France Microbiome Sequencing Services Market Research Report: By Technology (Sequencing by Litigation (SBL), Sequencing by Synthesis (SBS), Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, Others) andBy Application (Gastrointestinal Diseases, Infectious Diseases, CNS Diseases, Oncology, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 17.74%
- **2024:** $ 93.75 Million
- **2025:** $ 110.38 Million
- **2035:** $ 565 Million
- **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US)

**Report ID:** MRFR/HC/52148-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/france-microbiome-sequencing-services-market-53910

---

## Market Summary

## **France Microbiome Sequencing Services Market Overview****:**

As per MRFR analysis, the France Microbiome Sequencing Services Market Size was estimated at 70.97 (USD Million) in 2023. The France Microbiome Sequencing Services Market Industry is expected to grow from 78(USD Million) in 2024 to 437 (USD Million) by 2035. The France Microbiome Sequencing Services Market CAGR (growth rate) is expected to be around 16.959% during the forecast period (2025 - 2035).

### **Key France Microbiome Sequencing Services Market Trends Highlighted**

The France Microbiome Sequencing Services Market is undergoing substantial growth as a result of the growing emphasis on advanced healthcare solutions and personalized medicine. The French government has been making substantial investments in biotechnology research and development, acknowledging the critical role of the microbiome in the prevention of disease, nutrition, and health. 

This emphasis on research has facilitated collaborations between academic institutions and private firms, resulting in advancements in microbiome analysis and sequencing technologies. Various sectors, such as pharmaceuticals, food, and agriculture, are investigating the potential of microbiome applications, resulting in an expansion of market opportunities. For example, there is an increasing interest in the potential of the intestinal microbiota to impact drug efficacy and metabolism, which opens up opportunities for personalized treatments in clinical settings. In recent years, there has been a significant increase in public awareness of gastrointestinal health and its influence on overall wellness. 

The emergence of wellness culture in France has incited a surge in demand for sequencing services that offer personalized health reports, as consumers have begun to investigate their microbiome. Additionally, the French regulatory environment is changing to facilitate the development of innovative microbiome research, which has the potential to expedite the process of obtaining funding and resources for both established and startup companies.The combination of this regulatory support and the growing emphasis on preventive health and nutrition in society fosters a favorable environment for the development of microbiome sequencing services. 

Continuous advancements and deeper insights into the complex function of microbiomes in human health and disease management within France can be anticipated as companies align their strategies with these emerging trends.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

## **France Microbiome Sequencing Services Market Drivers**

### **Growing Demand for Personalized Medicine**

The demand for personalized medicine is driving growth in the France [Microbiome Sequencing Services Market](../../../reports/microbiome-sequencing-services-market-7532). Personalized medicine tailors healthcare treatment to individual characteristics, needs, and preferences, significantly improving patient outcomes. In France, the Ministry of Health has recognized personalized medicine as a key area for development, with initiatives undertaken to integrate genomic data into clinical practice. 

According to the French National Institute of Health and Medical Research, the market for personalized medicine could grow significantly, with projections indicating it could account for more than 5 billion Euros in the French healthcare budget by 2025.This increased investment in personalized medicine is likely to heighten the need for microbiome sequencing services that provide crucial insights into individual microbiomes, correlating with their health conditions, ultimately propelling market growth.

### **Advancements in Microbiome Research**

Significant advancements in microbiome research are pushing the France Microbiome Sequencing Services Market forward. With institutions like the Pasteur Institute leading cutting-edge studies, there has been a surge in the understanding of the human microbiome's role in health and disease.

Recent studies published in French scientific journals indicate that the microbiome influences conditions such as obesity, diabetes, and even mental health disorders - conditions on the rise within the population.The French National Research Agency has allocated several million Euros to research projects focused on microbiome studies, validating the research community's commitment to unraveling microbiome complexities, which boosts the demand for associated sequencing services, hence contributing to market growth.

### **Rising Investments in the Biotechnology Sector**

There has been a significant increase in investments in the biotechnology sector, which is positively influencing the France Microbiome Sequencing Services Market Industry. With the biotechnology sector expected to reach over 18 billion Euros by 2025, as indicated by the French Biotech Industry Association, this surge presents plentiful opportunities for microbiome sequencing service providers. Investments from venture capital firms and corporate partnerships are facilitating the development of advanced sequencing technologies and services.With companies like Genomic Health setting up operations in France to cater to the growing demand, it accelerates innovation, propelling growth in the microbiome sequencing services market.

### **Increased Public Awareness of Digestive Health**

Public awareness regarding the importance of digestive health and its connection to overall well-being has risen significantly, driving demand within the France Microbiome Sequencing Services Market Industry. Campaigns by health organizations, including local healthcare authorities and non-profits, underline the significance of gut health; a survey revealed that over 50% of the French population is now actively seeking information on maintaining gut health and microbiome balance.This awareness has led to an increased consumer willingness to invest in microbiome testing services that can provide personalized insights.

Businesses that supply microbiome sequencing and analysis services are responding to this demand, thus expanding their offerings and contributing to the market's upward trajectory.

## **France Microbiome Sequencing Services Market Segment Insights****:**

### **Microbiome Sequencing Services Market Technology Insights**

The France Microbiome Sequencing Services Market exhibits notable advancements in technology, driven by increasing research and development efforts focused on understanding microbiomes' role in health and disease. Sequencing by Litigation (SBL) involves analyzing legal questions related to genetic sequences, offering important insights for regulatory purposes, particularly in personal genomics and biobanking. Sequencing by Synthesis (SBS) aids in accurately generating DNA sequences and has gained attention due to its efficiency compared to traditional methods.

The Short Gun Sequencing technique enables comprehensive genomics analysis, making it particularly valuable for studies requiring deeper insights into microbial diversity and function. Targeted Gene Sequencing focuses on specific genes of interest, which is vital in both clinical diagnostics and therapeutic developments, allowing for personalized medicine approaches. RNA Sequencing is essential for understanding gene expression, providing data relevant for areas such as cancer research, thereby driving demand in both academic and commercial sectors.The inclusion of other methods adds diversity to the services offered, showcasing the market's adaptability to emerging technologies and innovative methodologies as it approaches a significant growth trajectory. 

The integration of these various sequencing technologies is reflected in the broader landscape of the France Microbiome Sequencing Services Market, enhancing the efficiency and reliability of microbiome studies. As companies continue to innovate and refine these techniques, the potential for valuable discoveries in healthcare, agriculture, and biotechnology in France remains promising, ultimately contributing to the overall market evolution and positioning.The growing emphasis on microbiome research correlates with increased public interest and investment focus, underscoring the pivotal nature of technological advancements within this dynamic sector.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

### **Microbiome Sequencing Services Market Application Insights**

The France Microbiome Sequencing Services Market focuses significantly on various applications, which include areas like Gastrointestinal Diseases, Infectious Diseases, Central Nervous System (CNS) Diseases, and Oncology. The growing understanding of the human microbiome's role in health and disease has accelerated research in these applications. Gastrointestinal Diseases particularly stand out, as advancements in microbiome research reveal how gut flora directly influences digestive health and overall wellness. 

Infectious Diseases are increasingly being studied through microbial sequencing, providing insights into pathogen resistance patterns and microbial diversity.Central Nervous System Diseases reflect another crucial segment where microbiome research is uncovering connections between gut health and neurological conditions, suggesting potential therapeutic avenues. Oncology also plays a key role, with emerging evidence linking microbiome composition to cancer treatment efficacy, impacting patient outcomes. 

Additionally, with ongoing advancements, there is substantial potential for other applications that harness microbiome insights, paving the way for novel therapeutic strategies. The France Microbiome Sequencing Services Market data shows that as knowledge expands, growth in these segments is likely to align with increasing healthcare investment, innovations in technology, and a robust Research and Development (R&D) ecosystem.Overall, the market exhibits a promising trajectory, supported by governmental initiatives pushing the boundaries of microbiome research, driving its importance across various healthcare applications.

## **France Microbiome Sequencing Services Market Key Players and Competitive Insights****:**

The France Microbiome Sequencing Services Market is characterized by its growing significance in the realms of healthcare, biotechnology, and environmental studies. This market has seen a surge in the demand for microbiome sequencing as industries recognize the potential of microbial communities in influencing human health, agricultural productivity, and ecological balance. With a competitive landscape comprising various providers of sequencing services, the market is driven by innovations in technology, diverse service offerings, and the establishment of robust research collaborations. 

Companies are vying for market share by enhancing their service capabilities, expanding geographic outreach, and differentiating their service portfolios to meet specific customer needs. The rise in investments supporting research and discovery in microbiome analysis is also shaping competitive dynamics within this sector.Zymo Research is a prominent player in the France Microbiome Sequencing Services Market, noted for its comprehensive range of services and innovative solutions. The company’s offerings include high-quality sample preparation kits, advanced sequencing technologies, and bioinformatics tools designed specifically for microbiome research.

Zymo Research's strength lies in its robust product portfolio that caters effectively to academic researchers, clinical laboratories, and commercial entities engaged in microbiome analysis.

The company's established reputation in molecular biology, combined with its commitment to providing reliable and reproducible results, contributes to its competitive position. Additionally, Zymo Research fosters partnerships with academic institutions and research organizations, which enhances its visibility and presence in the French market, enabling collaboration on significant microbiome studies and projects.Qiagen is another key competitor in the France Microbiome Sequencing Services Market, renowned for its sophisticated molecular testing solutions and versatile product range.

The company offers a complete suite of products and services geared towards microbiome research, including extraction kits, next-generation sequencing workflows, and bioinformatics software tailored for comprehensive data analysis.

Qiagen's market presence is fortified through its ongoing innovation, exemplified by the introduction of cutting-edge technologies that improve sequencing accuracy and efficiency. The company's strengths are further magnified by strategic mergers and acquisitions aimed at enhancing its capabilities in microbiome research, thereby broadening its service offerings and solidifying its market share in France. By continuously expanding its operational footprint and engaging with a diverse customer base, Qiagen maintains a competitive edge, effectively catering to the growing needs of researchers and practitioners in the microbiome domain across the region.

### **Key Companies in the France Microbiome Sequencing Services Market Include:**

- Zymo Research
- Qiagen
- Eurofins Scientific
- Nugen Technologies
- Thermo Fisher Scientific
- Illumina
- Molecular Assemblies
- BGI Group
- Oxford Nanopore Technologies
- Genewiz
- Genomatix
- Novogene
- Paragon Genomics
- DNA Genotek
- Swift Biosciences

## **France Microbiome Sequencing Services Market Industry Developments**

The France Microbiome Sequencing Services Market has seen significant developments recently, especially as awareness of the importance of the microbiome in human health increases. Companies such as Zymo Research, Qiagen, Eurofins Scientific, and Thermo Fisher Scientific continue to expand their offerings, catering to the growing demand for microbiome analysis in both research and clinical applications. Current market dynamics indicate rising investment in biotechnology research, driven by French governmental initiatives promoting innovation in health technologies. 

Furthermore, in August 2023, Illumina announced a strategic partnership with BGI Group to enhance integrative sequencing solutions within Europe, which is anticipated to boost operational capabilities in microbiome research. Additionally, Eurofins Scientific has been actively acquiring smaller biotech companies to expand its microbiome portfolio, reflecting a trend towards consolidation in the industry. Over the past couple of years, significant developments, such as the establishment of new research centers focusing on microbiome studies in Paris and Lyon, have contributed to the growth of this sector.

The overall valuation of the microbiome sequencing services market in France is expected to rise, as a combination of public and private sector investments continues to drive advances in sequencing technologies.

## **France Microbiome Sequencing Services Market Segmentation Insights**

### **Microbiome Sequencing Services Market Technology****Outlook**

- Sequencing by Litigation (SBL)
- Sequencing by Synthesis (SBS)
- Short Gun Sequencing
- Targeted Gene Sequencing
- RNA Sequencing
- Others

### **Microbiome Sequencing Services Market Application****Outlook**

- Gastrointestinal Diseases
- Infectious Diseases
- CNS Diseases
- Oncology
- Others

## Market Drivers

### Growing Awareness of Gut Health

The increasing awareness of the importance of gut health among the French population is driving the microbiome sequencing-services market. Consumers are becoming more informed about how gut microbiota influences overall health, including digestion, immunity, and mental well-being. This trend is reflected in the rising demand for microbiome analysis services, as individuals seek personalized insights into their gut health. According to recent surveys, approximately 60% of French consumers express interest in understanding their microbiome composition. This heightened awareness is likely to propel the market forward, as healthcare providers and wellness companies incorporate microbiome sequencing into their offerings, thereby enhancing the overall value proposition of the microbiome sequencing-services market.

### Supportive Regulatory Environment

The regulatory landscape in France appears to be increasingly supportive of innovations in the microbiome sequencing-services market. Government initiatives aimed at promoting biotechnology and personalized medicine are fostering an environment conducive to growth. For instance, funding programs and grants for research in microbiome studies are becoming more prevalent, encouraging companies to invest in sequencing technologies. The French government has allocated approximately €200 million to support health-related research, which includes microbiome studies. This supportive regulatory framework not only facilitates the development of new services but also enhances consumer trust in microbiome sequencing, thereby driving market expansion.

### Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases in France is a significant driver for the microbiome sequencing-services market. Conditions such as obesity, diabetes, and inflammatory bowel diseases are becoming increasingly common, prompting healthcare professionals to explore the role of the microbiome in disease management. Research indicates that alterations in gut microbiota may contribute to the onset of these conditions, leading to a growing interest in microbiome analysis as a diagnostic tool. As healthcare providers seek innovative solutions to address these health challenges, the demand for microbiome sequencing services is expected to rise. This trend suggests a potential market growth rate of around 15% annually, reflecting the increasing integration of microbiome insights into chronic disease management.

### Technological Innovations in Data Analysis

Technological advancements in data analysis are transforming the microbiome sequencing-services market. The emergence of sophisticated bioinformatics tools and machine learning algorithms enables researchers to interpret complex microbiome data more effectively. These innovations facilitate the identification of microbial patterns associated with health and disease, thereby enhancing the utility of microbiome sequencing services. In France, several startups are developing cutting-edge software solutions that streamline data processing and visualization, making it easier for healthcare providers to utilize microbiome insights in clinical practice. This trend indicates a growing reliance on technology to drive market growth, as improved data analysis capabilities enhance the overall value of microbiome sequencing services.

### Increased Collaboration Between Academia and Industry

The microbiome sequencing-services market is witnessing increased collaboration between academic institutions and industry players in France. This synergy is fostering innovation and accelerating the development of new sequencing technologies and applications. Universities and research centers are partnering with biotech companies to conduct studies that explore the implications of microbiome research on health and disease. Such collaborations often lead to the commercialization of research findings, thereby expanding the range of services available in the microbiome sequencing-services market. This trend is likely to enhance the competitive landscape, as new entrants emerge and existing companies innovate to meet the evolving demands of consumers and healthcare providers.

## Future Outlook

The [Microbiome Sequencing Services Market](https://www.marketresearchfuture.com/reports/microbiome-sequencing-services-market-7532) in France is projected to grow at a 17.74% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increasing health awareness, and technological innovations.

**New opportunities:**

- Development of targeted microbiome therapies for chronic diseases
- Expansion of subscription-based microbiome analysis services
- Partnerships with healthcare providers for integrated microbiome solutions

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Technology: Sequencing by Synthesis (Largest) vs. RNA Sequencing (Fastest-Growing)

Within the France microbiome sequencing-services market, Sequencing by Synthesis (SBS) dominates with a significant market share, widely adopted for its accuracy and high throughput. Other notable segments include Sequencing by Litigation (SBL) and Short Gun Sequencing, which offer distinct advantages in specific applications, though they hold comparatively smaller shares. Targeted Gene Sequencing and Others are also present, contributing to diverse market dynamics. 

The growth trends in this segment are driven by advancements in technology and increasing demand for high-resolution genomic data. RNA Sequencing is emerging as a key player, attributed to its capability in transcriptome analysis and growing applications in both research and clinical settings. The continuous innovation in sequencing methods and enhanced bioinformatics tools further propel this segment's expansion.

Technology: Sequencing by Synthesis (Dominant) vs. RNA Sequencing (Emerging)

Sequencing by Synthesis (SBS) is acknowledged as the dominant technology in the France microbiome sequencing-services market due to its robust accuracy, high throughput, and widespread application across diverse genomic studies. SBS supports large-scale projects and is favored in clinical diagnostics and research. In contrast, RNA Sequencing is recognized as an emerging technology, gaining momentum due to its specific utility in analyzing gene expression and regulation. This segment addresses the growing interest in understanding transcriptomes, making it a focal point for innovations within the market. As research prioritizes functional genomics and personalized medicine, both these technologies are poised to play critical roles in shaping the future landscape of sequencing services.

### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing)

In the France microbiome sequencing-services market, the application segment is primarily dominated by Oncology, capturing the largest market share due to its significant impact on cancer research and personalized medicine. Following closely, the Infectious Diseases segment is rapidly gaining traction, reflecting a growing focus on identifying and treating microbial infections more effectively through advanced sequencing technologies. This dual dynamic underscores the diverse applications of microbiome analysis across different health challenges.

Growth trends in this segment are significantly driven by increased research funding in cancer genomics and persistent public health concerns over infectious diseases. The rising prevalence of gastrointestinal and CNS diseases also contributes to the expansion of microbiome applications. Furthermore, continuous advancements in sequencing technology and increasing awareness of the microbiome's role in health are expected to foster innovation and growth in these segments, creating a robust ecosystem for future applications.

Oncology: Dominant vs. Infectious Diseases: Emerging

Oncology stands as the dominant application in the France microbiome sequencing-services market, leveraging cutting-edge research to enhance cancer diagnostics and treatment protocols. Its comprehensive analysis of tumor microbiomes aids in developing personalized therapeutic strategies, leading to improved patient outcomes. Conversely, the Infectious Diseases segment is emerging rapidly, highlighting the urgent need for precise microbial identification and antibiotic resistance studies. This segment benefits from innovative technologies that enable rapid sequencing, which is essential for effective disease management. As awareness grows regarding the microbiome's influence on immune responses, both segments are expected to thrive, bolstered by collaborative efforts between research institutions and healthcare providers.

## Competitive Benchmarking

The microbiome sequencing-services market in France is characterized by a dynamic competitive landscape, driven by increasing demand for personalized medicine and advancements in genomic technologies. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Qiagen (DE) are at the forefront, leveraging their technological expertise and extensive product portfolios to capture market share. Illumina (US) focuses on innovation in sequencing technologies, while Thermo Fisher Scientific (US) emphasizes comprehensive solutions for microbiome analysis. Qiagen (DE) is strategically positioned through its robust bioinformatics capabilities, which enhance data interpretation and application in clinical settings. Collectively, these strategies foster a competitive environment that prioritizes technological advancement and customer-centric solutions.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for dominance. However, the influence of major companies is substantial, as they set industry standards and drive innovation. This competitive structure encourages smaller firms to innovate and differentiate their offerings, thereby contributing to a vibrant market ecosystem.
In October 2025, Illumina (US) announced a partnership with a leading French research institution to develop next-generation sequencing applications tailored for microbiome research. This collaboration is expected to enhance the company’s product offerings and expand its reach within the European market. The strategic importance of this partnership lies in its potential to accelerate innovation and improve the accessibility of advanced sequencing technologies for researchers in France.
In September 2025, Thermo Fisher Scientific (US) launched a new suite of microbiome analysis tools designed to streamline workflows for clinical laboratories. This initiative reflects the company’s commitment to enhancing user experience and operational efficiency. By simplifying the analysis process, Thermo Fisher Scientific (US) positions itself as a leader in providing comprehensive solutions that cater to the evolving needs of the market.
In August 2025, Qiagen (DE) expanded its bioinformatics platform to include advanced analytics specifically for microbiome data interpretation. This enhancement is crucial as it allows researchers to derive actionable insights from complex datasets, thereby improving the overall utility of microbiome sequencing. Qiagen’s focus on bioinformatics underscores the growing importance of data analysis in the microbiome sequencing-services market.
As of November 2025, current competitive trends indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in microbiome research. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize R&D and customer-centric solutions will be better positioned to thrive in the future.

## Recent News & Developments

The France Microbiome Sequencing Services Market has seen significant developments recently, especially as awareness of the importance of the microbiome in human health increases. Companies such as Zymo Research, Qiagen, Eurofins Scientific, and Thermo Fisher Scientific continue to expand their offerings, catering to the growing demand for microbiome analysis in both research and clinical applications. Current market dynamics indicate rising investment in biotechnology research, driven by French governmental initiatives promoting innovation in health technologies. 

Furthermore, in August 2023, Illumina announced a strategic partnership with BGI Group to enhance integrative sequencing solutions within Europe, which is anticipated to boost operational capabilities in microbiome research. Additionally, Eurofins Scientific has been actively acquiring smaller biotech companies to expand its microbiome portfolio, reflecting a trend towards consolidation in the industry. Over the past couple of years, significant developments, such as the establishment of new research centers focusing on microbiome studies in Paris and Lyon, have contributed to the growth of this sector.

The overall valuation of the microbiome sequencing services market in France is expected to rise, as a combination of public and private sector investments continues to drive advances in sequencing technologies.

## Report Scope

| MARKET SIZE 2024 | 93.75(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 110.38(USD Million) |
| MARKET SIZE 2035 | 565.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.74% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Zymo Research (US), Qiagen (DE), Genomatix (DE), Microbiome Insights (CA), Second Genome (US), CosmosID (US) |
| Segments Covered | Technology, Application |
| Key Market Opportunities | Growing demand for personalized medicine drives innovation in the microbiome sequencing-services market. |
| Key Market Dynamics | Rising demand for personalized medicine drives innovation in microbiome sequencing-services, enhancing competitive dynamics in France. |
| Countries Covered | France |

## Frequently Asked Questions

**Q: What is the current valuation of the microbiome sequencing-services market in France?**
A: The market valuation was $93.75 Million in 2024.

**Q: What is the projected market size for the microbiome sequencing-services market in France by 2035?**
A: The market is projected to reach $565.0 Million by 2035.

**Q: What is the expected CAGR for the microbiome sequencing-services market in France during the forecast period 2025 - 2035?**
A: The expected CAGR is 17.74% during the forecast period.

**Q: Which companies are the key players in the microbiome sequencing-services market in France?**
A: Key players include Illumina, Thermo Fisher Scientific, Zymo Research, Qiagen, Genomatix, Microbiome Insights, Second Genome, and CosmosID.

**Q: What are the main technology segments in the microbiome sequencing-services market in France?**
A: Main technology segments include Sequencing by Litigation, Sequencing by Synthesis, Short Gun Sequencing, Targeted Gene Sequencing, RNA Sequencing, and Others.

**Q: What was the valuation of Sequencing by Synthesis in 2024?**
A: The valuation for Sequencing by Synthesis was $25.0 Million in 2024.

**Q: What is the projected valuation for Oncology applications in the microbiome sequencing-services market by 2035?**
A: The projected valuation for Oncology applications is $150.0 Million by 2035.

**Q: How does the valuation of Gastrointestinal Diseases compare to other applications in the market?**
A: Gastrointestinal Diseases had a valuation of $20.0 Million in 2024, which is lower than Oncology but higher than CNS Diseases.

**Q: What is the range of valuations for Short Gun Sequencing in the market?**
A: The range of valuations for Short Gun Sequencing is from $20.0 Million to $120.0 Million.

**Q: What are the potential growth opportunities in the microbiome sequencing-services market in France?**
A: Potential growth opportunities may arise from advancements in technology and increasing applications in various disease areas.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-microbiome-sequencing-services-market-53910*